
https://www.science.org/content/blog-post/ghrelin-and-obestatin
# Ghrelin and Obestatin (November 2005)

## 1. SUMMARY

This commentary discusses the discovery of obestatin, a peptide hormone that appears to have opposite effects to ghrelin—a hormone already being targeted by pharmaceutical companies for obesity and diabetes treatment. The author highlights that both hormones are derived from the same precursor protein, demonstrating the complexity of post-translational processing. Ghrelin stimulates feeding and increases gastric emptying in mice, while the newly discovered obestatin inhibits feeding and slows gastric emptying.

The article emphasizes how this discovery illustrates the limitations of purely genome-driven drug discovery approaches, since the same gene produces both hormones through alternative processing pathways. The author notes that the human genome contains far fewer genes than the number of known proteins, with examples like ghrelin-obestatin showing how much biological complexity exists downstream of DNA transcription.

## 2. HISTORY

The discovery of obestatin in 2005 generated significant initial excitement but ultimately did not translate into successful drug development as originally hoped. Subsequent research revealed a more complex picture:

**Obestatin's ambiguous clinical potential**: Extensive follow-up studies produced conflicting results about obestatin's effects on appetite regulation. Several research groups were unable to consistently reproduce the original findings that obestatin suppressed feeding in animals. The initial promise of obestatin as an anti-obesity therapeutic target largely failed to materialize, with no successful drug candidates reaching advanced clinical development.

**Ghrelin's continued pharmaceutical development**: While obestatin research stalled, ghrelin research continued but faced significant challenges. Despite ongoing efforts by pharmaceutical companies, developing effective ghrelin-based therapeutics proved difficult due to the hormone's pleiotropic effects—particularly its involvement in growth hormone signaling, which created undesirable side effect profiles.

**Mechanistic understanding evolved**: Further research revealed that both peptides have more complex and overlapping functions than initially understood. The simple opposition model (ghrelin stimulates, obestatin inhibits) proved incomplete, with context-dependent effects and interactions with other appetite-regulating pathways.

**No FDA-approved drugs resulted**: Neither ghrelin agonists/antagonists nor obestatin-based therapeutics achieved FDA approval for obesity or diabetes. The complexity of appetite regulation networks and the challenges of targeting peptide hormones limited clinical translation.

## 3. PREDICTIONS

The article made several explicit and implicit predictions:

- **Prediction**: Obestatin would prove to be an important appetite-suppressing hormone with therapeutic potential for obesity
  - **Reality**: Initial enthusiasm was not sustained; subsequent research showed inconsistent effects and no successful drug development resulted

- **Prediction**: The ghrelin-obestatin system would provide important new targets for obesity drug development
  - **Reality**: Despite continued research, neither ghrelin-based nor obestatin-based therapeutics achieved clinical success for obesity treatment

- **Prediction**: The discovery highlighted the limitations of genome-driven drug discovery approaches
  - **Reality**: This broader principle proved accurate and became widely accepted in pharmaceutical research, influencing drug discovery strategy

- **Implicit prediction**: This discovery would significantly advance understanding of appetite regulation
  - **Reality**: While it contributed to scientific knowledge, the practical impact on clinical treatment of obesity remained limited

## 4. INTEREST

**Rating: 6/10**

This article captures an interesting scientific moment where a new hormone discovery initially seemed promising for drug development, but ultimately illustrates how many early findings fail to translate into clinical applications—a valuable but cautionary example of biomedical research progression.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20051129-ghrelin-and-obestatin.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_